Oncoletter
Navigation überspringen
  • Kongressberichte & Archiv
    • SABCS - 42nd Annual San Antonio Breast Cancer Symposium
      • Press Conferences
        • Wednesday, Dec. 11
        • Thursday, Dec. 12
        • Friday, Dec. 13
      • General Sessions 1-6
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
      • Interviews - Breast Cancer
        • HER 2-positiver, metastasierter Brustkrebs: HER2CLIMB Studie mit Tucatinib
        • HER 2-positiver, metastasierter Brustkrebs: DESTINY-Breast01 Studie mit Trastuzumab Deruxtecan
        • HER 2-positiver Brustkrebs adjuvant: APHINITY Studie, 2. Zwischenanalyse
        • HER 2-positiver Brustkrebs adjuvant: ATEMPT Studie T-DM1 gegen Paclitaxel plus Trastuzumab
        • Einsatz von Capecitabine Neo/Adjuvant
        • GEPARX Studie: Denosumab im Vergleich zu zwei Nab-Paclitaxel Schemata - neoadjuvant
        • Immuncheckpoint-Inhibitoren: Durvalumab beim metastasierten BC und Pembrolizumab neoadjuvant und adjuvant bei TNBC
        • pCR bei neoadjuvanter Therapie mit Atezolizumab beim TNBC?
        • Neues zu CDK4/6 Inhibitoren (HR+ & HER2-)
        • Wenn der Brust-Tumor weg ist nach neoadjuvanter Therapie: Muss noch operiert werden?
        • Teil- oder Ganzbrustbestrahlung nach Brust erhaltender Therapie. Was für wen?
      • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
      • Round Table mit Brustkrebs Deutschland e.V.
    • 61st ASH Annual Meeting and Exposition
      • Highlights of the Conference: Statements & Opinions
        • ALL
        • Multiples Myelom
        • Multiples Myelom
        • Lymphome
      • Press Briefings
        • Saturday, December 7:
        • Saturday, December 7:
        • Saturday, December 7:
        • Sunday, December 8:
        • Monday, December 9 (embargoed until Tuesday 7:30 AM EST):
      • Late Breaking Abstract Session
      • Acute Lymphoblastic Leukemia (excluding Transplantation)
        • Therapeutic Strategies
        • Novel Therapies
        • Clinical Studies - Choice of Poster-Abstracts with Asparaginase
        • CAR T Cells--Refining the Approach
        • Chemo Immuno and Targets--Improving Combinations in ALL
      • Acute Myeloid Leukemia (excluding Transplantation)
        • Clinical Studies: Non-Intensive Therapy
        • Intensive Upfront Chemotherapy
        • Treatment of Relapsed/Refractory Disease
        • Induction and Post-Remission Therapy
        • New Treatment Strategies
        • Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs
        • Novel Targets and Combinations
      • Chronic Myeloid Leukemia: Therapy
        • Predictors of TKI Discontinuation and TFR Outcomes
        • Clinical Trials and Outcomes
        • Response Monitoring and Prognosis
      • Myeloproliferative Syndromes
        • Emerging and Novel Targeted Therapies
        • JAK Inhibitors and Combination Therapies
      • Myelodysplastic Syndromes
        • Combination Therapies
        • Targeting Gene Mutations in MDS
        • Lower-Risk MDS and CMML
        • SAKK POSTER
      • Myeloma: Therapy, excluding Transplantation
        • New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
        • Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
        • Therapeutics Questions in Newly Diagnosed Myeloma
        • Improving the Outcomes of Newly Diagnosed Multiple Myeloma
        • Novel Therapy for Relapsed Myeloma
      • CLL (excluding Transplantation)
        • First Line Treatment
        • Combination and Novel Treatment
        • BTK Inhibitors and CAR T Cells in CLL
      • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
        • Follicular Lymphoma: Biomarkers and Clinical Trials
        • Clinical Trials in Waldestrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas
        • Mantle Cell Lymphoma: Frontline and Relapsed Therapies
      • Hodgkin Lymphoma and T/NK Cell Lymphoma
        • Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma
        • Immunotherapy Approaches in Hodgkin Lymphoma
        • Novel Therapies in Peripheral T-cell Lymphomas
      • Aggressive Lymphoma (DLBC and Other Aggressive B-Cell Non-Hodgkin Lymphomas
        • Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy
        • Results from Prospective Clinical Trials: Results from CAR T-Cell Trials  
        • Novel Therapies in Relapsed/Refractory Disease
        • Results from Retrospective/Observational Studies: Population-Based Outcomes
        • Results from Retrospective/Observational Studies: Prognostic Markers
        • Results from Retrospective/Observational Studies: Cellular Therapies
      • Immunotherapies
        • Immunotherapies I
        • Immunotherapies II
      • Gene Therapy and Transfer
        • Advancing CAR T Cells: New Biology and Therapeutic Applications
        • Gene Therapies for Non-Malignant Disorders
    • 8. Interdisziplinäres Prostatakarzinom-Symposium 2019
      • I Grundlagen und Früherkennung
      • II Lokoregionäre Therapie des Prostatakarzinoms
      • III Aspekte der Systemtherapie des Prostatakarzinoms
    • Cancer Academy – Immuntherapie
    • Jahrestagung 2019 von DGHO, OeGHO, SGMO und SGH+SSH
      • Pressekonferenz
    • OnkoZentrum Zürich - Patientenforum 2019
    • ESMO 2019
      • Press Briefings
        • Opening Press Conference
        • Lung and gynaecological cancers
        • Breast cancer
        • Gastrointestinal and genitourinary cancers
      • SAKK Studien am ESMO 2019
      • Brustkrebs
      • Gastrointestinal Cancers
        • Metastatic Colorectal Cancer (mCRC)
        • More from BEACON CRC & TAILOR
        • Metastatic Gastric, Pancreatic & Biliary Cancer
      • Lung Cancer, Mesothelioma & Head and Neck Cancer
      • Melanoma
      • Ovarialkarzinom
    • Cancer Academy - Kopf-Hals-Tumore
    • CAR-T-Zell Therapie in der Schweiz
    • IASLC 2019 World Conference on Lung Cancer (#WCLC19)
      • Interviews
      • Press Briefings
        • Saturday, September 7th Press Briefing
        • Sunday, Sept. 8th Press Briefing
        • Monday, Sept 9th (Presidential Symposium Press Briefing)
        • Tuesday, Sept 10th Press Briefing
    • 4th Zurich Immuno-Oncology Symposium
      • Keynote Address
      • Therapeutic Developments I
      • Therapeutic Developments II
      • Challenges in Patient Management
      • Challenges in Optimizing Treatment
      • Cell-based Therapies
    • ESMO World Congress on Gastrointestinal Cancer
      • Press Conferences (News being made available according embargo rules)
        • Wednesday, 3 July - Opening Press Conference
        • Thursday, 4 July - Key studies of the day
        • Friday, 5 July - Key studies of the day
      • Session II: Cancer of the Pancreas and Biliary Tract
      • Presentation of Selected GI Cancer Abstracts
      • Presentation of Selected Rectal Cancer Abstracts
      • Session VII: Gastric Cancer - Presentation of Selected Abstracts
      • Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 1
      • Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 2
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 1
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 2
      • Session XVI: Hepatocellular Cancer - Presentation of Selected Abstracts
      • Session XX: Colorectal Cancer (Part I) - Presentation of Selected Abstracts & Comments Roger von Moos and Thomas Winder
    • Second Zurich Lung Cancer Symposium
      • Lung Cancer Screening and Approach to Small Lesions
      • Molecular Pathology of Lung Cancer
      • Development in Stage III NSCLC Disease
      • The Improvement of Survival in Metastatic NSCLC
      • The Importance of Clinical Trials
      • Approach to Oligometastatic Disease
    • 15th International Conference on Malignant Lymphoma (ICML)
      • Introductory Press Conference
      • PLENARY SESSION
      • MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?
      • HOW TO APPROACH CLL IN CLINICAL PRACTICE
      • THE MODERN APPROACH TO MANTLE CELL LYMPHOMA
      • MANTLE CELL LYMPHOMA
      • PET IMAGING
      • PEDIATRIC LYMPHOMA
      • RESULTS FROM SINGLE AGENT TRIALS
      • ONGOING TRIALS
      • DLBCL: CLINICAL DATA
      • CLL
      • TREATMENT WITH NOVEL ANTIBODIES
      • T-CELL LYMPHOMAS
      • CLL AND MORE
      • CHEMOTHERAPY-FREE STRATEGIES
      • NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
      • HIGH RISK LARGE B-CELL LYMPHOMAS
      • LYMPHOMA PATHOLOGY
      • HODGKIN LYMPHOMA
      • FOLLICULAR LYMPHOMA
      • EXTRANODAL LYMPHOMAS
      • NEW DATA ON T-CELL AND OTHER LYMPHOMAS
      • ADVANCES IN CAR T-CELL TREATMENT
      • NEW DRUG COMBINATIONS
      • INDOLENT NON-FOLLICULAR LYMPHOMA
    • 24th Congress of EHA
      • Presidential Symposium
      • Late-breaking oral presentations (6 best abstracts)
      • Important presentations at Press Briefings
        • Friday, June 14, 2019
        • Saturday, June 15, 2019
      • Indolent and mantle-cell non-Hodgkin Lymphoma - clinical
      • Aggressive lymphomas - New agents
      • Aggressive lymphomas - First line, combination therapy and real-life data - Aggressive non-Hodgkin lymphoma
      • Hodgkin lymphoma - clinical
      • Novel agents and therapies for CLL
      • New stratification and treatment approaches in ALL - including CAR T Cell therapy
      • Advances in the management of thalassemia
      • Immunotherapy in relapsed/refractory multiple myeloma
      • Novel strategies in multiple myeloma
      • Novel agents for newly diagnosed plasma cell dyscrasias
      • Myeloma and other monoclonal gammopathies - Clinical
      • New therapies in AML
      • Gene therapy, cellular immunotherapy and vaccination - Biology & translational research
      • Gene therapy, cellular immunotherapy and vaccination - Clinical
      • Update on clinical trials in MPN
      • New agents in MPN
    • Annual Meeting of the American Society of Clinical Oncology 2019
      • Press Briefings
        • May 15 Presscast
        • Press Briefing Saturday June 1:
        • Press Briefing Sunday June 2:
        • Press Briefing Monday June 3:
      • Breast Cancer
        • Breast Cancer News Interviews
          • Sind biosimilare Antikörper beim Brustkrebs genauso wirksam wie das Original?
          • Metastasierter HER2-positiver Brustkrebs
          • Immuntherapie bei Brustkrebs
          • MONALEESA 7: Überlebensvorteil für prämenopausale Frauen mit Ribociclib
          • Seltene Brustkrebsarten
          • Brustkrebs beim Mann
          • Lymphknotenbefall vor und nach neoadjuvanter Chemotherapie (transSENTINA 5)
          • T-DM1 neoadjuvant bei HER2-positivem Mammakarzinom (KRISTINE)
        • Breast Cancer News Aufzeichnung Live-Stream
        • Oral & Poster Presentations
      • Colon Cancer
        • Oral Presentations
        • Poster Presentations
      • Other gastrointestinal Cancer
        • Oral Presentations
        • Poster Presentations
      • Other Gynaecologic Cancers
      • Head & Neck Cancers
        • Oral Presentations
        • Poster Presentations
      • Lung Cancer
      • Hauttumore
      • Urogenital Cancers
        • Oral Presentations
        • Poster Presentations
      • Hematology
        • Multiple Myeloma & Myelofibrosis
        • Lymphoma & CLL
        • ALL
    • Senologie Update 2019
      • Teil 1:
      • Teil 2:
      • Teil 3:
      • Teil 4:
    • ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland
    • 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
      • Interviews
      • Presidential Symposium
        • GS2-2 - IMPROVED SURVIVAL OF AML- AND MDS-PATIENTS AFTER TREOSULFAN-BASED COMPARED TO REDUCED‑INTENSITY BUSULFAN-BASED CONDITIONING-REGIMEN FOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION: FINAL RESULTS OF A PROSPECTIVE RANDOMISED PHASE-III-TRIAL
        • GS2-3 - GRAFT-VERSUS-LEUKEMIA EFFECT AFTER HAPLO-IDENTICAL STEM-CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN AML- NO ASSOCIATION WITH GRAFT-VERSUS-HOST-DISEASE: A STUDY OF THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
        • GS2-4 - SEQUENTIAL CD19- AND CD22-CART CELL THERAPIES FOR RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 10-MONTH MEDIAN FOLLOW-UP
        • GS2-5 - ALLOGENEIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS VERSUS MATCHED OR MISMATCHED 9/10 UNRELATED DONORS IN ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
        • GS2-6 - LOW-DOSE INFUSIONS OF CD45RA DEPLETED DONOR LYMPHOCYTES AFTER
 TCR ALPHA/BETA-DEPLETED TRANSPLANTATION IN PATIENTS WITH NON-MALIGNANT DISORDERS
        • GS2-7 - CELL-MEDIATED IMMUNOGENICITY OF THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) IN ADULT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED ZOE-HSCT CLINICAL TRIAL
      • Oral Session 9: Late-breaking abstracts
        • OS9-1 - COMPARABLE OUTCOME AFTER 10/10 AND 9/10 HLA-MATCHED UNRELATED DONOR STEM CELL TRANSPLANTATION (HSCT) USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR GVHD PROPHYLAXIS, ON BEHALF OF THE ALWP-EBMT.
        • OS9-2 - MYELOABLATIVE CONDITIONING FOR FIRST ALLOGENEIC HSCT IN PEDIATRIC ALL: FTBI OR CHEMOTHERAPY? - AN UPDATE OF THE RETROSPECTIVE MULTICENTER EBMT-PDWP STUDY
        • OS9-3 - THE DETECTION OF THE SOLUBLE EBV ZEBRA PROTEIN AS A NEW PREDICTIVE BIOMARKER FOR PTLD
        • OS9-4 - EFFECTIVE CANCER IMMUNOTHERAPY WITH ERBB2-CAR-ENGINEERED CYTOKINE-INDUCED KILLER (CIK) CELLS IN HIGH-RISK SOFT TISSUE SARCOMAS
        • OS9-5 - GENESIS - A PHASE III RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EVALUATING SAFETY AND EFFICACY OF BL-8040 AND G-CSF IN MOBILIZATION OF HCS´S FOR AUTOLOGOUS TRANSPLANTATION-MULTIPLE MYELOMA
        • OS9-6 - REAL LIFE EXPERIENCE IN THE TREATMENT OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT ALL PATIENTS USING COMMERCIALLY AVAILABLE CAR-T-CELLS
      • How Do I... manufacture T cells for cellular therapies
        • HDI1-1 - Manufacturing of virus-specific T cells at an academic center
        • HDI1-2 - CAR T manufacturing in an academic setting
        • HDI1-3 - Low-dose memory T cell DLI for infection prophylaxis
      • How Do I... manage patients after CAR T-cell therapy.
        • HDI8-1 - Lymphoma, CLL and ALL
        • HDI8-2 - Myeloma patients
        • HDI8-3 - From a nurse's perspective
      • New developments in the field of CAR cell therapy
        • P2-1 - State of the art for ex-vivo manufactured autologous CAR T-cells
        • P2-2 - Simultaneous targeting of CD19 and CD22 with a bicistronic CAR - preliminary results of the AMELIA study
        • P2-3 - Off-the-shelf CAR NK cells for the treatment of hematologic malignancies
        • P2-4 - CAR T-cells against solid tumors: TRUCKs on the road
    • BCC2019
      • Opening and Award Ceremony:
      • Session 1: News since St.Gallen 2017
      • Session 2: Biology of Breast Cancer I: Risk stratification
      • Session 3: Biology of breast cancer II: Prediction of response
      • Session 4: Risk stratification and prevention in ductal in situ carcinoma
      • Special lecture I and II
      • Session 5: New pathways with potential impact in the treatment of early breast cancer
      • Session 6: Treatment tailoring according to pathology and biology
      • Session 7: Surgery of early breast cancer
      • Session 8: Radiotherapy of early breast cancer
      • Special lecture III
      • Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I
      • Session 10: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit II
      • GenomicHealth interactive satellite symposium in conjunction with the 16th St Gallen International Breast Cancer Conference
      • Nanostring Satellite Symposium: Recent Breakthroughs for HR+/HER2- Early Breast Cancer Patients:
      • Interviews (in German): Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
      • Three SAKK Posters
    • AGO MAMMAKARZINOM - State of the Art Meeting 2019
      • Vormittag 1
      • Vormittag 2
      • Nachmittag 1
      • Nachmittag 2
      • Interviews: Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
    • First Zürich Precision Oncology Symposium
      • Speakers
      • Molecular Testing and Molecular Tumor Board
      • Keynote address
      • Precision Oncology for Solid Tumors 1/Ongoing Research Activities 1
      • Precision Oncology for Solid Tumors 2
      • Precision Oncology for Hematologic Malignancies
      • Precision Oncology for Solid Tumors 2/Ongoing Research Activities 2
    • The Gastrointestinal Cancers Symposium 2019
      • ASSOC.PROF. PD DR. GERALD PRAGER, WIEN: Cancers of the Esophagus and Stomach - the Highlights
      • General Session 1:
      • General Session 2:
      • Rapid Abstract Session A:
      • Breakout Session: Palliation of Esophago-Gastric Malignancies
      • Oral Abstract Session A:
      • General Session 3:
      • Poster Walks:
      • Rapid Abstract Session B:
      • Breakout Session: Novel Innovations in Pancreatic and Hepatobiliary Malignancies
      • Welcome and General Session 4:
      • General Session 5:
      • Keynote Lecture: Kelly McMasters
      • ASSOC.PROF. PD DR. GERALD PRAGER, WIEN: Cancers of the Pancreas - the Highlights
      • Oral Abstract Session B:
      • General Session 6:
      • Poster Walks:
      • liposomal irinotecan (nal-IRI) 2nd line & neoadjuvant
      • PD DR. MED. DOMINIK MODEST, MÜNCHEN - Colon Cancer - Personal Highlights
      • Rapid Abstract Session C:
      • Welcome and Keynote Lecture:
      • Breakout Session: The Latest Updates on HIPEC for Gastrointestinal Cancers
      • General Session 7:
      • Oral Abstract Session C:
      • Poster Walks:
      • General Session 8:
      • General Session 9:
      • POSTER SESSIONS A,B,C
      • Trials in Progress Poster Session A, B, C
      • Presentations with trifluridine/tipiracil (FTD/TPI) at the Gastrointestinal Cancers Symposium
    • SABCS - 41st Annual San Antonio Breast Cancer Symposium
      • Press Conferences
        • Wednesday, Dec. 5, Press Conference 1
        • Wednesday, Dec. 5, Press Conference 2
        • Thursday, Dec. 6 Press Conference
        • Friday, Dec. 7 Press Conference
      • Schweizer Poster am SABCS
      • Interviews - Breast Cancer
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Achim Rody, Lübeck
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle/Saale
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Priv.-Doz. Dr. med. Hans-Christian Kolberg in Bottrop
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Sibylle Loibl, Frankfurt
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. Rachel Würstlein, München
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Jörg Schilling, Berlin
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Priv.-Doz. Dr. med. Hans-Christian Kolberg, Bottrop
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Lothar Müller, Onkologie Unterems
      • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
      • Round Table mit Brustkrebs Deutschland e.V.
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
    • American Society of Hematology (ASH) 60th Annual Meeting and Exposition
      • Statements & Opinions from some Highlights of the Conference
        • PD Dr. med. Nicolas Bonadies, Bern
        • Prof. Dr. med. Christoph Driessen, St. Gallen
        • Prof. Dr. med. Christoph Renner, Zürich
      • Press Briefings
        • Saturday December 1
          • Improving Sickle Cell Disease Outcomes in the U.S. and Africa
          • Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders
          • CAR T-Cell Therapies: New Research and Updates from Pivotal Trials
        • Sunday December 2
        • Monday December 3
          • Late-Breaking Abstracts - Non-Malignant
          • Late-Breaking Abstracts - Malignant
      • Late-Breaking Abstracts Session
      • Myeloma: Therapy and upfront autologous Transplantation
        • Novel Antibody Combinations in Myeloma
        • Novel Targeted Combinations in Myeloma
        • Antibodies and Targeted Therapies
        • Novel Proteasome Inhibitors
        • Immunotherapies in Plasma Cell Disorders
        • Immunotherapy
        • Upfront Autologous Transplantation
        • Choice of Myeloma Posters
      • AML
        • Acute Myeloid Leukemia - Clinical Studies
          • Immunotherapy and New Agents
          • Minimal Residual Disease and Genetic Characterization
          • Maintenance after Allogeneic Stem Cell Transplant and Management of Refractory/Relapsed AML
        • Acute Myeloid Leukemia - Commercially Available Therapy, excluding Transplantation:
          • Optimal Induction and Re-Induction Regimens For Acute Myeloid Leukemia
          • Targeted Therapy For Adults Diagnosed With Acute Myeloid Leukemia
        • Acute Myeloid Leukemia - Novel Therapy, excluding Transplantation
          • Combination Therapy
          • Targeted Therapy
          • New Treatment Strategies
          • Immunotherapy
      • Lymphoma
        • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
          • Prognostic Markers and Therapies in Mantle Cell Lymphoma and Waldenstrom's Macroglobulinemia
          • Novel Therapies and Prognostic Assessment in Hairy Cell Leukemia and Indolent Non-Hodgkin Lymphoma
          • Antibodies, Immunomodulators, and BTK Inhibitors in Indolent NHL
        • Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
          • Immunotherapy and Targeted Strategies
          • Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches
          • T Cell Lymphoma: Chemotherapy and Targeted Approaches
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials
          • Immunotherapy
          • New Agents
          • Initial Treatment
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies
          • Outcomes With CD19 CAR T Therapy and Checkpoint Blockade in the Real World Setting
          • Prognostic Biomarkers and Molecular Signatures for Risk Stratification
          • Population Based Outcomes in Aggressive Lymphoma
          • Outcomes Of Lymphoma In The Elderly
      • Acute Lymphoblastic Leukemia: Clinical Studies & Therapy Excluding Transplantations
        • Improving Outcomes with Cellular Therapy
        • Improving Frontline Therapy in ALL
        • Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
        • Targeted Therapy in ALL: Immunotherapy and Beyond
      • CLL: Therapy, excluding Transplantation:
        • Measurable Residual Disease in CLL: Moving Towards a Cure
        • Cellular Therapy and Immunomodulation in CLL
        • Advances in CLL Using Novel Combination Therapy
      • Chronic Myeloid Leukemia: Therapy
        • Epidemiology, Prognosis, and Real Life Care
        • First Line Trials and Prognostic Factors of Treatment-Free Remission
        • TFR Failure, Resistance, and New Drug Development
      • Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics, Prognosis and Prediction
        • Novel Therapeutics I
        • Novel Therapeutics II
        • Prognosis and Prediction
      • Scientific, medical, clinical, relevant “asparaginase” related Presentations
      • Health Services & Outcome Research—Malignant Diseases
      • Clinical Trials for Hemophilia and Using CAR T Cells
      • Thalassemia and Globin Gene Regulation
    • Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
    • ESMO 2018 Congress
      • Press Briefings
        • Breast Cancer
        • Ovarian Cancer
        • Prostate & Kidney Cancers
        • Head & Neck Cancer
        • All ESMO 2018 Press Releases
      • Interviews
        • Interviews - Breast Cancer
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Sven Mahner, München
        • Statement Summary GIT-Cancers
        • Statements Colorectal Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Gastric Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Lung Cancer
        • Statement Renal Cell Carcinoma
      • Links to selected presentations and abstracts
        • Presidential Sessions
          • Presidential Session 1
          • Presidential Session 2
          • Presidential Session 3
        • Selection of Posters
          • 464P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
          • 1290P - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program (EAP)
          • 509P - Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): a FIRE-3 analysis
          • 481P - Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial
          • 549P - Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: the plasma RAS wild type “window of opportunity”
          • 1068P - Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), a phase Ib – randomized phase II study versus single agent MTX
    • Archiv 2018
      • Cancer Academy - Blut- und Lymphdrüsenkrebs
      • Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
        • Keynote address
        • Clinical results, patient cases and future developments I
        • Clinical results, patient cases and future developments II
        • Clinical results, patient cases and future developments III
        • Developments in immunotherapy
      • 20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
        • Session I: Welcome with Selected Abstracts
        • Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
        • Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
        • Pancreatic Cancer: Poster Session
        • Session VII: Gastric Cancer: Presentation of selected abstracts
        • Session VIII: Diseases and Cancers of the Liver: Presentation of a selected abstract
        • Session XI: Presentation of Selected Abstracts: Colorectal Cancer
        • Session XX: Colorectal Cancer: Presentation of selected abstracts
      • 23rd Congress of EHA
        • Presidential Symposium
        • Plenary Session Abstracts
        • Press Briefings
          • Press Briefing Day 1
          • Press Briefing Day 2
        • Important AML Presentations
          • IDHm and BCL2 inhibitors in AML
          • One AML Poster
        • Important CLL Presentations
        • Important Multiple Myeloma Presentations
          • Advances in front-line treatment of newly diagnosed multiple myeloma
          • New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders
          • Multiple Myeloma Poster Presentations
          • One Multiple Myeloma Late Breaking Abstract
        • Important Lymphoma Presentations
        • Thalassemia (2 Presentations) & MDS (1 Presentation)
      • Annual Meeting of the American Society of Clinical Oncology 2018
        • Highlights of the day
          • Sunday
          • Monday
          • Tuesday
        • Press Briefings
          • May 16 Presscast
          • Press Briefing 1 Friday June 1:
          • Press Briefing 2 Saturday June 2:
          • Press Briefing 3 Sunday June 3:
          • Press Briefing 4 Monday June 4:
        • Breast Cancer
          • Breast Cancer News from Oral Sessions
          • Breast Cancer News from Poster Sessions
          • Breast Cancer News Interviews
        • Colon Cancer
          • Colon Cancer News from Poster Sessions
        • Lung Cancer
          • Lung Cancer News from oral sessions
        • Lymphoma
          • Lymphoma News Oral Sessions
          • Lymphoma News Poster Sessions
        • Merkel-Cell Carcinoma
        • Myeloid Diseases
          • Myeloid Diseases News from Oral Sessions
          • Myeloid Diseases News from Poster Sessions
        • Other Hematologic Malignancies
        • Pancreatic Cancer
          • Pancreatic Cancer News from Oral Sessions
          • Pancreatic Cancer News from Poster Sessions
        • Urologic Cancers
          • Renal Cancer
      • ESMO Preceptorship on Colorectal Cancer 2018
      • SENOLOGIE update 2018
        • Prophylaktische Mastektomie - Moderation: M. Knauer, St. Gallen
        • Psychosoziale Konsequenzen des Mammakarzinoms - Moderation: E. Sarasin, Zürich
        • Update Systemtherapie - Moderation: U. Breitenstein, Zürich
        • Varia - Moderation: E. Saurenmann, Zürich
      • Cancer Academy - Darmkrebs
      • AACR Annual Meeting 2018, April 14-18,
        • Highlights presented at the Press Conference Sunday, April 15
        • Highlights presented at the Press Conference Monday, April 16
        • Highlights presented at the Press Conference Tuesday, April 17
      • ELCC 2018 (European Lung Cancer Congress)
        • Highlights - Press Releases
        • Interviews
          • Conference Highlights
          • Interviews in Cooperation with the Video Journal of Oncology - Part 1
        • SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
      • 11th European Breast Cancer Conference (EBCC-11)
        • Press conferences
        • Important News
        • Interviews
          • PD Dr. med. Christian Kolberg, Bottrop
          • Prof. Dr. med. Thorsten Kühn, Esslingen
          • Prof. Dr. med. Nadia Harbeck, München
      • St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
        • Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?
        • Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy
        • Session 3: Treatment Modalities for Oesophago-Gastric Cancer
        • Session 4: Special situation I: Signet Ring Cell Cancer
        • Keynote: Hereditary Gastric Cancer
        • New Therapy Options by metastatic Colorectal Cancer
        • Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer
        • Session 6: Ready for Practice?
        • EORTC Gastrointestinal Tract Cancer Group:
      • Cancer Academy - Prostatakrebs
      • Promoting Self-efficacy with Digital Tools
        • Welcome (German)
        • Promoting patients’ self-efficacy: How can it be successful? (German)
        • United Kingdom’s perspective on the use of digital solutions to improve cancer patients’ self-efficacy
        • Presentation of selected digital and patient-oriented applications
          • Consilium: Patient-centered communication for improved self-efficacy and quality of life
          • STREAM – Ein online Programm zur Unterstützung bei Belastung während einer Krebserkrankung
          • Symptom Navi: Förderung des Selbstmanagements von Symptomen bei Krebs
          • Entspannung und Achtsamkeit für Krebspatienten mit Hilfe einer App (CanRelax)
          • FertiOnco – an online approach to facilitate decision making in young female cancer patients regarding fertility preservation
        • The use of patient-reported outcomes to improve outcomes and quality in cancer care
        • Digital solutions for cancer patients: reach, (cost-) effectiveness and implementation
        • Discussion and Closing remarks (German)
      • Gastrointestinal Cancers Symposium Jan 18-20, 2018 San Francisco, California
        • Cancers of the Esophagus and Stomach
        • Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
          • Videostatements
          • Studies presented in oral sessions
          • Posters
          • Posters
        • Cancers of the Colon, Rectum, and Anus
          • Videostatement
          • Studies presented in oral sessions
          • Choice of Posters
    • Archiv 2017
      • 59th ASH Annual Meeting and Exposition
        • Late-Breaking Abstracts Session
        • AML
          • Oral Sessions
        • Multiple Myeloma
          • Oral Sessions
          • Choice of Posters
        • Lymphoma
          • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • CLL: Therapy, excluding Transplantation:
        • Press Conferences
          • Novel Approaches to Hemophilia and Venous Thromboembolism Care
          • Engineering Solutions to Treat Inherited Blood Disorders
          • Enhancing Care in Hematologic Malignancies through Targeted Therapies
          • Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies
          • Late-Breaking Abstracts
        • Interviews
          • Statement Christian Taverna, Münsterlingen
          • Statement Thorsten Zenz, Zürich
      • 40th Annual San Antonio Breast Cancer Symposium (SABCS)
        • General Sessions
          • GENERAL SESSION 1:
          • GENERAL SESSION 2:
          • GENERAL SESSION 3:
          • GENERAL SESSION 4:
          • GENERAL SESSION 5:
          • GENERAL SESSION 6:
        • Press Conferences
          • Wednesday December 6 @ 7:15 a.m.
          • Wednesday December 6 @ 12:15 p.m
          • Thursday December 7 @ 7:30 am
          • Friday December 8 @ 7:30 am
        • Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable
          • Roundtable Brustkrebs Deutschland
          • Roundtable mit Experten aus der Schweiz
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin (Kopie)
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Stefan Buchholz, Regensburg
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Thorsten Kühn, Esslingen
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Dr. phil. Ute Berndt, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr.med. Michael Untch, Berlin-Buch
      • Cancer Academy – Hirntumoren
      • 7. Interdisziplinäres Prostatakarzinomsymposium
        • Grundlagen
        • Lokalisiertes & oligometastatisches Prostatakarzinom
        • Systemtherapien Prostatakarzinom
      • Advanced Breast Cancer 4th ESO-ESMO International Consensus Conference
      • Cancer Academy – Brustkrebs
      • ESMO 2017 Congress
        • Breast Cancer Highlights
          • Neoadjuvante Therapie bei luminalem, triple negativem oder HER2 positivem Brustkrebs
          • Luminaler Brustkrebs - wer braucht Chemotherapie?
          • CDK4-6 Inhibitoren beim metastasierten Brustkrebs
          • Abstract LBA10_PR ‘Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)’
          • Abstract 1472P_PR ‘Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients’
        • Gastrointestinal Carcinoma Highlights
          • Colorectal Cancer
          • Gastric Cancer
        • Head & Neck Cancer Highlights
          • PD Dr. med. Sacha Rothschild comments Head&Neck Cancer Studies
          • Abstract LBA45_PR ‘Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial’
          • 1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
          • 1. First line Cetuximab and Cisplatin with or without Paclitaxel/2. The observational ENCORE study: Cetuximab + platinum-based therapy
        • Lung Cancer Highlights
          • Prof. Martin Reck
          • PD Dr. AlessandraCurioni-Fontecedro
          • PD Dr. AlessandraCurioni-Fontecedro
          • Prof. Dr. med.Solange Peters
          • Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
        • Melanoma & Merkel Cell Carcinoma Highlights
          • Prof. Dr. med. Reinhard Dummer, Zurich
          • Prof. Dr. med. Olivier Michielin, Lausanne
        • Ovarian Cancer Highlights
        • Urogenital Cancer Highlights
          • Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights
          • Abstract LBA37_PR – ‘Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial’
        • Late breaking news
          • Opening Press Conference
          • LBA Press Conference: Lung cancer
          • Press Conference: Facing the challenges of life after cancer
          • LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers
          • LBA Press Conference: Melanoma cancer
          • Wrap-Up press conference/Best of ESMO2017
      • Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium
        • Welcome
        • Essentials of tumour immunology and immunotherapies
        • Clinical results, patient cases and future developments I
        • Clinical results, patient cases and future developments II
        • Clinical results, patient cases and future developments III
        • Management of toxicities
      • ESMO 19th World Congress on Gastrointestinal Cancer
        • Cancer of the Pancreas
          • Session II: Cancer of the Pancreas & bile Ducts
          • Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology
          • Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
          • Interview mit Prof. Gerald Prager, Wien
        • Colon Cancer Highlights
          • Session XIX: Colorectal Cancer
          • Prof. Dr. med. Bernhard Pestalozzi, UniversitätsSpital Zürich:
      • Die besonderen Bedürfnisse von Kindern und Jugendlichen mit Krebs
      • 14 The International Conference on Malignant Lymphoma (ICML)
        • Interviews & Introductory Press Conference
          • Introductory Press Conference
          • Lymphoma Therapy
          • Oncoletter Interviews in cooperation with VJHEMONC
        • Satellite Symposia
          • THE FIRST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
          • CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
      • ASCO Annual Meeting 2017
        • ASCO Press Conferences
          • ASCO Annual Meeting 2017 Presscast May 17
          • ASCO Annual Meeting 2017 Presscast June 2
          • ASCO Annual Meeting 2017 Presscast June 3 Part 1
          • ASCO Annual Meeting 2017 Presscast June 3 Part 2
          • ASCO Annual Meeting 2017 Presscast June 4
          • ASCO Annual Meeting 2017 Presscast June 5
        • Online-Programm verbessert die Lebensqualität von Krebspatienten
        • Highlights Mammakarzinom
          • Brustkrebs Deutschland: Experten-Roundtable vom ASCO Annual Meeting 2017
          • HER2-positiver, primär metastasierter Brustkrebs
          • HER2-positiver metastasierter Brustkrebs
          • PARP-Inhibitoren bei Brustkrebs
          • Abemaciclib bei Brustkrebs-Hirnmetastasen
          • HER2-positiver, primär metastasierter Brustkrebs
          • Scalp-Cooling - Chemo ohne Haarverlust?
          • CDK 4-6 Inhibitoren: Palbociclib, Ribociclib, Abemaciclib
          • Ergebnisse der Aphinity-Studie für HER 2 neu-positiven Brustkrebs adjuvant
          • Stellungnahme zur Relevanz von Studienendpunkten und deren Akzeptanz am runden Tisch: Wir alle müssen umdenken!
          • Finale Ergebnisse der PlanB-Studie für klinische Hochrisikopatientinnen bzw. mit mittlerem bis hohem Risiko nach Genexpressionstest
          • Short-HER-Studie:Sind 9 Wochen Trastuzumab nicht schlechter als 1 Jahr?
          • I-Spy 2-Studie: Immuntherapie mit Pembrolizumab plus Standard neoadjuvante Therapie für Hochrisikopatientinnen
        • Highlights Ovarialkarzinom
          • LION Studie: Rolle der Lymphknotenentfernung bei Erstoperation des Eierstockkrebs
          • DESKTOP 3 Studie: Erneute OP beim Eierstockkrebs Rezidiv
          • Immuntherapie bei Vulva-, Zervix- und Ovarialkarzinom: gibt es schon Einsatzmöglichkeit?
          • PARP-Inhibitoren beim Eierstockkrebs: welcher, wann und wie lange?
        • Head & Neck Cancer Highlights
          • Highlights Head&Neck
          • Statements Sacha Rothschild, Jean Bourhis & Marco Merlano
          • Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)
        • Highlights Gastrointestinaltumoren
          • Upper GIT
          • Colon Cancer
          • Pancreatic Cancer
        • Haematologic Malignancies
      • ELCC 2017 Genf
      • Cancer Academy – Lungenkrebs: Früherkennung, Diagnose und Behandlung
      • SENOLOGIE update 2017
        • Radiologie - Moderation: F. Dammann, Zürich
        • Genetik - Moderation: R. Morant, Rapperswil
        • Qualitätssicherung in der Senologie - Moderation: C. Rageth, Zürich
        • Operative Therapie - Moderation: C. Tausch, Zürich
        • Das metastasierte Mammakarzionom - Moderation: A. Müller, Winterthur
        • Varia - Moderation: D. Fink, Zürich
      • 15th St.Gallen International Breast Cancer Conference
      • Symposium Thoracic Oncology – Guidelines and Beyond
        • Screening
        • Inquiring the molecular tumor characteristics
        • Shanghai meets Zürich
        • Treatment options in localized NSCLC
        • Multimodality approaches in rare thoracic tumors
        • Metastatic disease
    • Archiv 2016
      • Das elektronische Patientendossier: das Genfer Beispiel der Integration eines Spitals in eine Referenzgemeinschaft
      • IASLC 17TH WORLD CONFERENCE ON LUNG CANCER
        • Fachpressemitteilungen
          • Lungenkrebs-Weltkongress in Wien: Aktive Prävention, akkurate Diagnostik, aktuelle Fortschritte in der Behandlung
          • Mutations-Diagnostik setzt sich bei Lungenkrebs durch
          • Mikro-RNA zur Prognosebestimmung bei Mesotheliom-Erkrankungen
          • Therapeutische Impfung gegen Lungenkrebs:
          • Zweite Therapiechance für Lungenkarzinompatienten
      • 58th Annual Meeting of the American Society of Hematology
        • PRESS CONFERENCES
          • Developing Novel Therapies and Unique Delivery Methods to Improve Treatment for Bleeding Crises, Leukemia
          • Revolutionizing Sickle Cell Disease Care in the United States and Abroad
          • Improved Outcomes in Leukemia, Trauma Settings with Personalized Medicine Approaches
        • Choice of ASH presentations
          • 616: Acute Myeloid Leukemia
          • Lymphoma
          • 642. CLL
          • 653. Myeloma
          • 637. Myelodysplastic Syndromes
          • 904. Outcomes Research
          • 112. Thalassemia and Globin Gene Regulation
        • Interviews Best of ASH (Multiples Myelom, Lymphome)
      • Zürich, 25. November 2016: 6. Treffen von Krebspatientinnen und -patienten
      • ESMO-Congress, Oct 07-11, 2016 - Copenhagen, Denmark
        • Press Conferences
          • Friday 7 October - Opening Press Conference
          • Saturday 8 October Press Conference 1: Late Breaking Trials
          • Sunday 9 October Press Conference 2: Late Breaking Trials
          • Monday 10 October Press Conference 3: Late Breaking Trials
        • More Highlights
          • Metastatic Colorectal Cancer
      • Cancer Center Zürich First Zurich Immuno-Oncology Symposium
        • Essentials of tumour immunology and immunotherapies
        • Clinical results, patient cases and future developments I
        • Clinical results, patient cases and future developments II
        • Clinical results, patient cases and future developments III
        • Management of toxicities
        • Radiotherapy
      • Das elektronische Patientendossier als zentrales Instrument der interprofessionellen Zusammenarbeit in integrierten Versorgungsorganisationen
      • WCGIC - 18th World Congress on Gastrointestinal Cancer
        • Metastatic & non-metastatic Colorectal Cancer
          • Statements Ulrich Güller, Andreas Wicki, Thomas Winder
        • ESMO PRESS RELEASES
          • Regorafenib shows significant survival gains in refractory liver cancer
          • Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo
          • Chemoradiotherapy after surgery for gastric cancer shows similar outcomes to post-operative chemotherapy.
          • Anti-PD-L1 immunotherapy shows response in microsatellite-stable metastatic colorectal cancer in combination with MEK inhibition
        • Satellite Symposia
          • Developing a continuum of care for patients with metastatic pancreatic cancer: A case study-based debate
          • mCRC Myth-Busters reloaded: More facts for optimal patient benefit!
      • Zürich, 1. Juli 2016: 5. Treffen von Krebspatientinnen und -patienten
      • Bern, Donnerstag 29. Juni 2016: Den Patienten integrieren - ein Symposium der Nationale Strategie gegen Krebs:
      • The 21st EHA Annual Congress
        • EHA Highlights presented at the press conference
          • Friday June 10
          • Saturday June 11
      • 36. Jahrestagung Deutsche Gesellschaft für Senologie 25.–28. Mai 2016, Dresden
        • Das Wichtigste vom Tage
        • Lunchsymposium: Genomic Health – Oncotype DX
        • Interviews
      • SENOLOGIE update 2016
        • Diagnostik - Moderation: M. Bürge, Zürich
        • Operative Therapie - Moderation: C. Tausch, Zürich
        • Über- oder Untertherapie? - Moderation: D. Fink, Zürich
        • Update Onkologie - Moderation: H-J. Senn, St. Gallen
        • Varia - Moderation: E. Saurenmann, Zürich
      • ELCC 2016 | European Lung Cancer Conference - ESMO
        • News
          • Osimertinib given as first-line treatment may alter biology of EGFR mutated non-small-cell lung cancer
          • Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma
          • Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy
          • Studies confirm benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer
        • Interviews
      • 3rd Gastrointestinal Cancer Conference
        • Thursday March 10
          • Session 1: Cystic Neoplasms of the Pancreas
          • Session 2: Biliary Tract - Extrahepatic Cholangiocarcinoma I
          • Keynote I: Molecular biology of pancreatic cancer
          • Session 3: Biliary Tract - Extrahepatic Cholangiocarcinoma II
          • Session 4: Cancer of the Ampulla of Vater
        • Friday March 11
          • Session 5: Understanding Pancreatic Cancer
          • Session 6: Resectable Pancreatic Cancer
          • Satellite symposium organized by Celgene
          • Session 7: Borderline Resectable Pancreatic Cancer
          • Session 8: Improving Outcome in Pancreatic Cancer
      • Symposium Nationale Strategie gegen Krebs:
      • WEF DAVOS: Cancer Moonshot: A Call to Action
  • Livecasts & Kongresskalender
    • Livecast
    • Kongresskalender 2019
    • Kongresskalender 2020
  • Drugs oral & i.v., Guidelines, Interaktionen
    • Orale Krebstherapeutika
      • orale Wirkstoffe A
      • orale Wirkstoffe B
      • Orale Wirkstoffe C
      • Orale Wirkstoffe D
      • Orale Wirkstoffe E
      • Orale Wirkstoffe G
      • Orale Wirkstoffe H
      • Orale Wirkstoffe I
      • Orale Wirkstoffe L
      • Orale Wirkstoffe Ν
      • Orale Wirkstoffe O
      • Orale Wirkstoffe P
      • Orale Wirkstoffe R
      • Orale Wirkstoffe S
      • Orale Wirkstoffe T
      • Orale Wirkstoffe V
    • Wirkstoffe
      • Melden Sie fehlende Wirkstoffe
      • Acronyme
      • ALK-Inhibitors
      • Wirkstoffe A
      • Wirkstoffe B
      • Wirkstoffe C
      • Wirkstoffe D
      • Wirkstoffe E
      • Wirkstoffe F
      • Wirkstoffe G
      • Wirkstoffe H
      • Wirkstoffe I
      • Wirkstoffe L
      • Wirkstoffe M
      • Wirkstoffe N
      • Wirkstoffe O
      • Wirkstoffe P
      • Wirkstoffe Q
      • Wirkstoffe R
      • Wirkstoffe S
      • Wirkstoffe T
      • Wirkstoffe V
      • Wirkstoffe Z
    • Behandlungsguidelines
    • Journal of Oncoletter
    • The Cancer Cell Line Encyclopedia
    • Texte zur Medizinischen Onkologie aus dem Swiss Medical Forum
    • Oncologic emergencies
    • Interaktionsprüfungen
    • Krebserkrankungen (Entstehung & Verlauf)
      • Krebserkrankungen B
      • Krebserkrankungen D
      • Krebserkrankungen E
      • Krebserkrankungen G
      • Krebserkrankungen H
      • Krebserkrankungen L
      • Krebserkrankungen M
      • Krebserkrankungen N
      • Krebserkrankungen P
      • Krebserkrankungen S
    • Wissenschaftlicher Beirat Oncoletter
  • Nebenwirkungen & Behandlungs- vorschläge
    • Symptome
      • Allgemeine Störungen
        • Fatigue
        • Fieber/Infektion
        • Ödeme
        • Schmerzen
        • Stimmungsschwankungen
      • Atmungsorgane
        • Dyspnoe
        • Epistaxis/Nasenbluten
        • Pleuraerguss
      • Augen
        • Konjunktivitis
        • Periorbitale Oedeme
        • Sehstoerungen
      • Blut- und Lymphsystem
        • Anaemie
        • Lymphopenie
        • Neutropenie
        • Thrombozytopenie
      • Gastrointestinale Störungen
        • Abdominalschmerz
        • Diarrhoe
        • Dyspepsie
        • Mukositis/Stomatitis
        • Nausea und Erbrechen
        • Obstipation
      • Haut
        • Aktinische Keratose
        • Alopezie
        • Hand-Fuss-Syndrom
        • Hyperkeratose
        • Photosensivitätsreaktion
        • Plattenepithelkarzinom der Haut
        • Praevention von Pruritus, Rash, Desquamation
        • Pruritus
        • Rash, papulopustulöse, follikuläre Exantheme
        • Seborrhoische Keratose
        • Sonnenbrand
        • Trockene Haut
      • Herz, Gefässe
        • Arterielle Hypertonie
        • Blutungen
        • Herzinsuffizienz
        • Hitzewallungen
        • Verminderung der linksventrikulären Auswurfsfraktion (LVEF)
      • Leber und Galle
        • Dosierungsempfehlungen oraler TKI/mTor-Inhibitoren bei Leberdysfunktion
        • Gamma-Glutamyl-Transferase
      • Muskelskelettsystem
        • Arthralgien
        • Knochenschmerzen
        • Muskelschwaeche
        • Muskelverhaertungen und Muskelkraempfe
        • Muskuloskelettale Beschwerden/Schmerzen in den Extremitaeten/Gliederschmerzen
        • Myalgie/Muskelschmerzen
        • Rueckenschmerzen
      • Nervensystem
        • Dysgeusie
        • Insomnie
        • Kopfschmerzen
        • Neuropathie/Polyneuropathie
        • Reversible posteriore Leukenzephalopathie
      • Niere und ableitende Harnwege
        • Harnwegsinfekt
      • Stoffwechsel- und Ernährungsstörungen
        • Amylase-/Lipasewerte
        • Anorexie
        • Cholesterol- oder Triglyzeridwerte
        • Gewichtszunahme
        • Glucosewerte
        • Hypokaliämie
        • Hypokalzämie
        • Hypophosphatämie
        • Hypothyreose
    • Referenzen
    • Nutzungsbestimmungen
  • Organisationen
    • Fachgesellschaften
    • Info für PatientINNen
    • Netzwerke
 
Navigation überspringen

Navigation/Menu

 
Navigation überspringen
  • Kongressberichte & Archiv
    • SABCS - 42nd Annual San Antonio Breast Cancer Symposium
      • Press Conferences
        • Wednesday, Dec. 11
        • Thursday, Dec. 12
        • Friday, Dec. 13
      • General Sessions 1-6
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
      • Interviews - Breast Cancer
        • HER 2-positiver, metastasierter Brustkrebs: HER2CLIMB Studie mit Tucatinib
        • HER 2-positiver, metastasierter Brustkrebs: DESTINY-Breast01 Studie mit Trastuzumab Deruxtecan
        • HER 2-positiver Brustkrebs adjuvant: APHINITY Studie, 2. Zwischenanalyse
        • HER 2-positiver Brustkrebs adjuvant: ATEMPT Studie T-DM1 gegen Paclitaxel plus Trastuzumab
        • Einsatz von Capecitabine Neo/Adjuvant
        • GEPARX Studie: Denosumab im Vergleich zu zwei Nab-Paclitaxel Schemata - neoadjuvant
        • Immuncheckpoint-Inhibitoren: Durvalumab beim metastasierten BC und Pembrolizumab neoadjuvant und adjuvant bei TNBC
        • pCR bei neoadjuvanter Therapie mit Atezolizumab beim TNBC?
        • Neues zu CDK4/6 Inhibitoren (HR+ & HER2-)
        • Wenn der Brust-Tumor weg ist nach neoadjuvanter Therapie: Muss noch operiert werden?
        • Teil- oder Ganzbrustbestrahlung nach Brust erhaltender Therapie. Was für wen?
      • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
      • Round Table mit Brustkrebs Deutschland e.V.
    • 61st ASH Annual Meeting and Exposition
      • Highlights of the Conference: Statements & Opinions
        • ALL
        • Multiples Myelom
        • Multiples Myelom
        • Lymphome
      • Press Briefings
        • Saturday, December 7:
        • Saturday, December 7:
        • Saturday, December 7:
        • Sunday, December 8:
        • Monday, December 9 (embargoed until Tuesday 7:30 AM EST):
      • Late Breaking Abstract Session
      • Acute Lymphoblastic Leukemia (excluding Transplantation)
        • Therapeutic Strategies
        • Novel Therapies
        • Clinical Studies - Choice of Poster-Abstracts with Asparaginase
        • CAR T Cells--Refining the Approach
        • Chemo Immuno and Targets--Improving Combinations in ALL
      • Acute Myeloid Leukemia (excluding Transplantation)
        • Clinical Studies: Non-Intensive Therapy
        • Intensive Upfront Chemotherapy
        • Treatment of Relapsed/Refractory Disease
        • Induction and Post-Remission Therapy
        • New Treatment Strategies
        • Novel Immunotherapeutics, Checkpoint Inhibitors, and BiTEs
        • Novel Targets and Combinations
      • Chronic Myeloid Leukemia: Therapy
        • Predictors of TKI Discontinuation and TFR Outcomes
        • Clinical Trials and Outcomes
        • Response Monitoring and Prognosis
      • Myeloproliferative Syndromes
        • Emerging and Novel Targeted Therapies
        • JAK Inhibitors and Combination Therapies
      • Myelodysplastic Syndromes
        • Combination Therapies
        • Targeting Gene Mutations in MDS
        • Lower-Risk MDS and CMML
        • SAKK POSTER
      • Myeloma: Therapy, excluding Transplantation
        • New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
        • Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
        • Therapeutics Questions in Newly Diagnosed Myeloma
        • Improving the Outcomes of Newly Diagnosed Multiple Myeloma
        • Novel Therapy for Relapsed Myeloma
      • CLL (excluding Transplantation)
        • First Line Treatment
        • Combination and Novel Treatment
        • BTK Inhibitors and CAR T Cells in CLL
      • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
        • Follicular Lymphoma: Biomarkers and Clinical Trials
        • Clinical Trials in Waldestrom's Macroglobulinemia and Other Indolent B-cell Non-Hodgkin Lymphomas
        • Mantle Cell Lymphoma: Frontline and Relapsed Therapies
      • Hodgkin Lymphoma and T/NK Cell Lymphoma
        • Combination Chemotherapy and Biomarkers of Response in Hodgkin Lymphoma
        • Immunotherapy Approaches in Hodgkin Lymphoma
        • Novel Therapies in Peripheral T-cell Lymphomas
      • Aggressive Lymphoma (DLBC and Other Aggressive B-Cell Non-Hodgkin Lymphomas
        • Results from Prospective Clinical Trials: Optimizing Frontline Chemotherapy
        • Results from Prospective Clinical Trials: Results from CAR T-Cell Trials  
        • Novel Therapies in Relapsed/Refractory Disease
        • Results from Retrospective/Observational Studies: Population-Based Outcomes
        • Results from Retrospective/Observational Studies: Prognostic Markers
        • Results from Retrospective/Observational Studies: Cellular Therapies
      • Immunotherapies
        • Immunotherapies I
        • Immunotherapies II
      • Gene Therapy and Transfer
        • Advancing CAR T Cells: New Biology and Therapeutic Applications
        • Gene Therapies for Non-Malignant Disorders
    • 8. Interdisziplinäres Prostatakarzinom-Symposium 2019
      • I Grundlagen und Früherkennung
      • II Lokoregionäre Therapie des Prostatakarzinoms
      • III Aspekte der Systemtherapie des Prostatakarzinoms
    • Cancer Academy – Immuntherapie
    • Jahrestagung 2019 von DGHO, OeGHO, SGMO und SGH+SSH
      • Pressekonferenz
    • OnkoZentrum Zürich - Patientenforum 2019
    • ESMO 2019
      • Press Briefings
        • Opening Press Conference
        • Lung and gynaecological cancers
        • Breast cancer
        • Gastrointestinal and genitourinary cancers
      • SAKK Studien am ESMO 2019
      • Brustkrebs
      • Gastrointestinal Cancers
        • Metastatic Colorectal Cancer (mCRC)
        • More from BEACON CRC & TAILOR
        • Metastatic Gastric, Pancreatic & Biliary Cancer
      • Lung Cancer, Mesothelioma & Head and Neck Cancer
      • Melanoma
      • Ovarialkarzinom
    • Cancer Academy - Kopf-Hals-Tumore
    • CAR-T-Zell Therapie in der Schweiz
    • IASLC 2019 World Conference on Lung Cancer (#WCLC19)
      • Interviews
      • Press Briefings
        • Saturday, September 7th Press Briefing
        • Sunday, Sept. 8th Press Briefing
        • Monday, Sept 9th (Presidential Symposium Press Briefing)
        • Tuesday, Sept 10th Press Briefing
    • 4th Zurich Immuno-Oncology Symposium
      • Keynote Address
      • Therapeutic Developments I
      • Therapeutic Developments II
      • Challenges in Patient Management
      • Challenges in Optimizing Treatment
      • Cell-based Therapies
    • ESMO World Congress on Gastrointestinal Cancer
      • Press Conferences (News being made available according embargo rules)
        • Wednesday, 3 July - Opening Press Conference
        • Thursday, 4 July - Key studies of the day
        • Friday, 5 July - Key studies of the day
      • Session II: Cancer of the Pancreas and Biliary Tract
      • Presentation of Selected GI Cancer Abstracts
      • Presentation of Selected Rectal Cancer Abstracts
      • Session VII: Gastric Cancer - Presentation of Selected Abstracts
      • Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 1
      • Session XII: Presentation of Selected Abstracts: Emerging New or Combination Drugs in GI Cancer Part 2
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 1
      • Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 2
      • Session XVI: Hepatocellular Cancer - Presentation of Selected Abstracts
      • Session XX: Colorectal Cancer (Part I) - Presentation of Selected Abstracts & Comments Roger von Moos and Thomas Winder
    • Second Zurich Lung Cancer Symposium
      • Lung Cancer Screening and Approach to Small Lesions
      • Molecular Pathology of Lung Cancer
      • Development in Stage III NSCLC Disease
      • The Improvement of Survival in Metastatic NSCLC
      • The Importance of Clinical Trials
      • Approach to Oligometastatic Disease
    • 15th International Conference on Malignant Lymphoma (ICML)
      • Introductory Press Conference
      • PLENARY SESSION
      • MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?
      • HOW TO APPROACH CLL IN CLINICAL PRACTICE
      • THE MODERN APPROACH TO MANTLE CELL LYMPHOMA
      • MANTLE CELL LYMPHOMA
      • PET IMAGING
      • PEDIATRIC LYMPHOMA
      • RESULTS FROM SINGLE AGENT TRIALS
      • ONGOING TRIALS
      • DLBCL: CLINICAL DATA
      • CLL
      • TREATMENT WITH NOVEL ANTIBODIES
      • T-CELL LYMPHOMAS
      • CLL AND MORE
      • CHEMOTHERAPY-FREE STRATEGIES
      • NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
      • HIGH RISK LARGE B-CELL LYMPHOMAS
      • LYMPHOMA PATHOLOGY
      • HODGKIN LYMPHOMA
      • FOLLICULAR LYMPHOMA
      • EXTRANODAL LYMPHOMAS
      • NEW DATA ON T-CELL AND OTHER LYMPHOMAS
      • ADVANCES IN CAR T-CELL TREATMENT
      • NEW DRUG COMBINATIONS
      • INDOLENT NON-FOLLICULAR LYMPHOMA
    • 24th Congress of EHA
      • Presidential Symposium
      • Late-breaking oral presentations (6 best abstracts)
      • Important presentations at Press Briefings
        • Friday, June 14, 2019
        • Saturday, June 15, 2019
      • Indolent and mantle-cell non-Hodgkin Lymphoma - clinical
      • Aggressive lymphomas - New agents
      • Aggressive lymphomas - First line, combination therapy and real-life data - Aggressive non-Hodgkin lymphoma
      • Hodgkin lymphoma - clinical
      • Novel agents and therapies for CLL
      • New stratification and treatment approaches in ALL - including CAR T Cell therapy
      • Advances in the management of thalassemia
      • Immunotherapy in relapsed/refractory multiple myeloma
      • Novel strategies in multiple myeloma
      • Novel agents for newly diagnosed plasma cell dyscrasias
      • Myeloma and other monoclonal gammopathies - Clinical
      • New therapies in AML
      • Gene therapy, cellular immunotherapy and vaccination - Biology & translational research
      • Gene therapy, cellular immunotherapy and vaccination - Clinical
      • Update on clinical trials in MPN
      • New agents in MPN
    • Annual Meeting of the American Society of Clinical Oncology 2019
      • Press Briefings
        • May 15 Presscast
        • Press Briefing Saturday June 1:
        • Press Briefing Sunday June 2:
        • Press Briefing Monday June 3:
      • Breast Cancer
        • Breast Cancer News Interviews
          • Sind biosimilare Antikörper beim Brustkrebs genauso wirksam wie das Original?
          • Metastasierter HER2-positiver Brustkrebs
          • Immuntherapie bei Brustkrebs
          • MONALEESA 7: Überlebensvorteil für prämenopausale Frauen mit Ribociclib
          • Seltene Brustkrebsarten
          • Brustkrebs beim Mann
          • Lymphknotenbefall vor und nach neoadjuvanter Chemotherapie (transSENTINA 5)
          • T-DM1 neoadjuvant bei HER2-positivem Mammakarzinom (KRISTINE)
        • Breast Cancer News Aufzeichnung Live-Stream
        • Oral & Poster Presentations
      • Colon Cancer
        • Oral Presentations
        • Poster Presentations
      • Other gastrointestinal Cancer
        • Oral Presentations
        • Poster Presentations
      • Other Gynaecologic Cancers
      • Head & Neck Cancers
        • Oral Presentations
        • Poster Presentations
      • Lung Cancer
      • Hauttumore
      • Urogenital Cancers
        • Oral Presentations
        • Poster Presentations
      • Hematology
        • Multiple Myeloma & Myelofibrosis
        • Lymphoma & CLL
        • ALL
    • Senologie Update 2019
      • Teil 1:
      • Teil 2:
      • Teil 3:
      • Teil 4:
    • ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland
    • 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
      • Interviews
      • Presidential Symposium
        • GS2-2 - IMPROVED SURVIVAL OF AML- AND MDS-PATIENTS AFTER TREOSULFAN-BASED COMPARED TO REDUCED‑INTENSITY BUSULFAN-BASED CONDITIONING-REGIMEN FOR ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION: FINAL RESULTS OF A PROSPECTIVE RANDOMISED PHASE-III-TRIAL
        • GS2-3 - GRAFT-VERSUS-LEUKEMIA EFFECT AFTER HAPLO-IDENTICAL STEM-CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN AML- NO ASSOCIATION WITH GRAFT-VERSUS-HOST-DISEASE: A STUDY OF THE ACUTE LEUKEMIA WORKING PARTY OF EBMT
        • GS2-4 - SEQUENTIAL CD19- AND CD22-CART CELL THERAPIES FOR RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 10-MONTH MEDIAN FOLLOW-UP
        • GS2-5 - ALLOGENEIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS VERSUS MATCHED OR MISMATCHED 9/10 UNRELATED DONORS IN ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
        • GS2-6 - LOW-DOSE INFUSIONS OF CD45RA DEPLETED DONOR LYMPHOCYTES AFTER
 TCR ALPHA/BETA-DEPLETED TRANSPLANTATION IN PATIENTS WITH NON-MALIGNANT DISORDERS
        • GS2-7 - CELL-MEDIATED IMMUNOGENICITY OF THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) IN ADULT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED ZOE-HSCT CLINICAL TRIAL
      • Oral Session 9: Late-breaking abstracts
        • OS9-1 - COMPARABLE OUTCOME AFTER 10/10 AND 9/10 HLA-MATCHED UNRELATED DONOR STEM CELL TRANSPLANTATION (HSCT) USING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR GVHD PROPHYLAXIS, ON BEHALF OF THE ALWP-EBMT.
        • OS9-2 - MYELOABLATIVE CONDITIONING FOR FIRST ALLOGENEIC HSCT IN PEDIATRIC ALL: FTBI OR CHEMOTHERAPY? - AN UPDATE OF THE RETROSPECTIVE MULTICENTER EBMT-PDWP STUDY
        • OS9-3 - THE DETECTION OF THE SOLUBLE EBV ZEBRA PROTEIN AS A NEW PREDICTIVE BIOMARKER FOR PTLD
        • OS9-4 - EFFECTIVE CANCER IMMUNOTHERAPY WITH ERBB2-CAR-ENGINEERED CYTOKINE-INDUCED KILLER (CIK) CELLS IN HIGH-RISK SOFT TISSUE SARCOMAS
        • OS9-5 - GENESIS - A PHASE III RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, EVALUATING SAFETY AND EFFICACY OF BL-8040 AND G-CSF IN MOBILIZATION OF HCS´S FOR AUTOLOGOUS TRANSPLANTATION-MULTIPLE MYELOMA
        • OS9-6 - REAL LIFE EXPERIENCE IN THE TREATMENT OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT ALL PATIENTS USING COMMERCIALLY AVAILABLE CAR-T-CELLS
      • How Do I... manufacture T cells for cellular therapies
        • HDI1-1 - Manufacturing of virus-specific T cells at an academic center
        • HDI1-2 - CAR T manufacturing in an academic setting
        • HDI1-3 - Low-dose memory T cell DLI for infection prophylaxis
      • How Do I... manage patients after CAR T-cell therapy.
        • HDI8-1 - Lymphoma, CLL and ALL
        • HDI8-2 - Myeloma patients
        • HDI8-3 - From a nurse's perspective
      • New developments in the field of CAR cell therapy
        • P2-1 - State of the art for ex-vivo manufactured autologous CAR T-cells
        • P2-2 - Simultaneous targeting of CD19 and CD22 with a bicistronic CAR - preliminary results of the AMELIA study
        • P2-3 - Off-the-shelf CAR NK cells for the treatment of hematologic malignancies
        • P2-4 - CAR T-cells against solid tumors: TRUCKs on the road
    • BCC2019
      • Opening and Award Ceremony:
      • Session 1: News since St.Gallen 2017
      • Session 2: Biology of Breast Cancer I: Risk stratification
      • Session 3: Biology of breast cancer II: Prediction of response
      • Session 4: Risk stratification and prevention in ductal in situ carcinoma
      • Special lecture I and II
      • Session 5: New pathways with potential impact in the treatment of early breast cancer
      • Session 6: Treatment tailoring according to pathology and biology
      • Session 7: Surgery of early breast cancer
      • Session 8: Radiotherapy of early breast cancer
      • Special lecture III
      • Session 9: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit I
      • Session 10: Primary and adjuvant systemic therapy of early breast cancer: Estimating the magnitude of clinical benefit II
      • GenomicHealth interactive satellite symposium in conjunction with the 16th St Gallen International Breast Cancer Conference
      • Nanostring Satellite Symposium: Recent Breakthroughs for HR+/HER2- Early Breast Cancer Patients:
      • Interviews (in German): Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
      • Three SAKK Posters
    • AGO MAMMAKARZINOM - State of the Art Meeting 2019
      • Vormittag 1
      • Vormittag 2
      • Nachmittag 1
      • Nachmittag 2
      • Interviews: Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch
    • First Zürich Precision Oncology Symposium
      • Speakers
      • Molecular Testing and Molecular Tumor Board
      • Keynote address
      • Precision Oncology for Solid Tumors 1/Ongoing Research Activities 1
      • Precision Oncology for Solid Tumors 2
      • Precision Oncology for Hematologic Malignancies
      • Precision Oncology for Solid Tumors 2/Ongoing Research Activities 2
    • The Gastrointestinal Cancers Symposium 2019
      • ASSOC.PROF. PD DR. GERALD PRAGER, WIEN: Cancers of the Esophagus and Stomach - the Highlights
      • General Session 1:
      • General Session 2:
      • Rapid Abstract Session A:
      • Breakout Session: Palliation of Esophago-Gastric Malignancies
      • Oral Abstract Session A:
      • General Session 3:
      • Poster Walks:
      • Rapid Abstract Session B:
      • Breakout Session: Novel Innovations in Pancreatic and Hepatobiliary Malignancies
      • Welcome and General Session 4:
      • General Session 5:
      • Keynote Lecture: Kelly McMasters
      • ASSOC.PROF. PD DR. GERALD PRAGER, WIEN: Cancers of the Pancreas - the Highlights
      • Oral Abstract Session B:
      • General Session 6:
      • Poster Walks:
      • liposomal irinotecan (nal-IRI) 2nd line & neoadjuvant
      • PD DR. MED. DOMINIK MODEST, MÜNCHEN - Colon Cancer - Personal Highlights
      • Rapid Abstract Session C:
      • Welcome and Keynote Lecture:
      • Breakout Session: The Latest Updates on HIPEC for Gastrointestinal Cancers
      • General Session 7:
      • Oral Abstract Session C:
      • Poster Walks:
      • General Session 8:
      • General Session 9:
      • POSTER SESSIONS A,B,C
      • Trials in Progress Poster Session A, B, C
      • Presentations with trifluridine/tipiracil (FTD/TPI) at the Gastrointestinal Cancers Symposium
    • SABCS - 41st Annual San Antonio Breast Cancer Symposium
      • Press Conferences
        • Wednesday, Dec. 5, Press Conference 1
        • Wednesday, Dec. 5, Press Conference 2
        • Thursday, Dec. 6 Press Conference
        • Friday, Dec. 7 Press Conference
      • Schweizer Poster am SABCS
      • Interviews - Breast Cancer
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Patrick Lux, Erlangen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Achim Rody, Lübeck
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Nadia Harbeck, München:
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle/Saale
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Cornelia Liedtke, Berlin
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Priv.-Doz. Dr. med. Hans-Christian Kolberg in Bottrop
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Thorsten Kühn, Esslingen
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Wilhelm Braun, München
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Sibylle Loibl, Frankfurt
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Prof. Dr. med. Michael Untch, Berlin-Buch
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. Rachel Würstlein, München
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Jörg Schilling, Berlin
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Priv.-Doz. Dr. med. Hans-Christian Kolberg, Bottrop
        • Dr. Petra Ortner, JOURNAL ONKOLOGIE im Gespräch mit Dr. med. Lothar Müller, Onkologie Unterems
      • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
      • Round Table mit Brustkrebs Deutschland e.V.
      • General Sessions
        • GENERAL SESSION 1:
        • GENERAL SESSION 2:
        • GENERAL SESSION 3:
        • GENERAL SESSION 4:
        • GENERAL SESSION 5:
        • GENERAL SESSION 6:
    • American Society of Hematology (ASH) 60th Annual Meeting and Exposition
      • Statements & Opinions from some Highlights of the Conference
        • PD Dr. med. Nicolas Bonadies, Bern
        • Prof. Dr. med. Christoph Driessen, St. Gallen
        • Prof. Dr. med. Christoph Renner, Zürich
      • Press Briefings
        • Saturday December 1
          • Improving Sickle Cell Disease Outcomes in the U.S. and Africa
          • Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders
          • CAR T-Cell Therapies: New Research and Updates from Pivotal Trials
        • Sunday December 2
        • Monday December 3
          • Late-Breaking Abstracts - Non-Malignant
          • Late-Breaking Abstracts - Malignant
      • Late-Breaking Abstracts Session
      • Myeloma: Therapy and upfront autologous Transplantation
        • Novel Antibody Combinations in Myeloma
        • Novel Targeted Combinations in Myeloma
        • Antibodies and Targeted Therapies
        • Novel Proteasome Inhibitors
        • Immunotherapies in Plasma Cell Disorders
        • Immunotherapy
        • Upfront Autologous Transplantation
        • Choice of Myeloma Posters
      • AML
        • Acute Myeloid Leukemia - Clinical Studies
          • Immunotherapy and New Agents
          • Minimal Residual Disease and Genetic Characterization
          • Maintenance after Allogeneic Stem Cell Transplant and Management of Refractory/Relapsed AML
        • Acute Myeloid Leukemia - Commercially Available Therapy, excluding Transplantation:
          • Optimal Induction and Re-Induction Regimens For Acute Myeloid Leukemia
          • Targeted Therapy For Adults Diagnosed With Acute Myeloid Leukemia
        • Acute Myeloid Leukemia - Novel Therapy, excluding Transplantation
          • Combination Therapy
          • Targeted Therapy
          • New Treatment Strategies
          • Immunotherapy
      • Lymphoma
        • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies
          • Prognostic Markers and Therapies in Mantle Cell Lymphoma and Waldenstrom's Macroglobulinemia
          • Novel Therapies and Prognostic Assessment in Hairy Cell Leukemia and Indolent Non-Hodgkin Lymphoma
          • Antibodies, Immunomodulators, and BTK Inhibitors in Indolent NHL
        • Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies
          • Immunotherapy and Targeted Strategies
          • Hodgkin Lymphoma: Chemotherapy and Response Adapted Approaches
          • T Cell Lymphoma: Chemotherapy and Targeted Approaches
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials
          • Immunotherapy
          • New Agents
          • Initial Treatment
        • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies
          • Outcomes With CD19 CAR T Therapy and Checkpoint Blockade in the Real World Setting
          • Prognostic Biomarkers and Molecular Signatures for Risk Stratification
          • Population Based Outcomes in Aggressive Lymphoma
          • Outcomes Of Lymphoma In The Elderly
      • Acute Lymphoblastic Leukemia: Clinical Studies & Therapy Excluding Transplantations
        • Improving Outcomes with Cellular Therapy
        • Improving Frontline Therapy in ALL
        • Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
        • Targeted Therapy in ALL: Immunotherapy and Beyond
      • CLL: Therapy, excluding Transplantation:
        • Measurable Residual Disease in CLL: Moving Towards a Cure
        • Cellular Therapy and Immunomodulation in CLL
        • Advances in CLL Using Novel Combination Therapy
      • Chronic Myeloid Leukemia: Therapy
        • Epidemiology, Prognosis, and Real Life Care
        • First Line Trials and Prognostic Factors of Treatment-Free Remission
        • TFR Failure, Resistance, and New Drug Development
      • Myelodysplastic Syndromes—Clinical Studies: Novel Therapeutics, Prognosis and Prediction
        • Novel Therapeutics I
        • Novel Therapeutics II
        • Prognosis and Prediction
      • Scientific, medical, clinical, relevant “asparaginase” related Presentations
      • Health Services & Outcome Research—Malignant Diseases
      • Clinical Trials for Hemophilia and Using CAR T Cells
      • Thalassemia and Globin Gene Regulation
    • Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
    • ESMO 2018 Congress
      • Press Briefings
        • Breast Cancer
        • Ovarian Cancer
        • Prostate & Kidney Cancers
        • Head & Neck Cancer
        • All ESMO 2018 Press Releases
      • Interviews
        • Interviews - Breast Cancer
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Michael Untch, Berlin-Buch
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Volkmar Müller, Hamburg
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Christian Jackisch, Offenbach
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
          • Renate Haidinger, Vorsitzende Brustkrebs Deutschland e.V. im Interview mit Prof. Dr. med. Sven Mahner, München
        • Statement Summary GIT-Cancers
        • Statements Colorectal Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Gastric Cancer
          • Statement Alexander Meisel, Zürich
        • Statements Lung Cancer
        • Statement Renal Cell Carcinoma
      • Links to selected presentations and abstracts
        • Presidential Sessions
          • Presidential Session 1
          • Presidential Session 2
          • Presidential Session 3
        • Selection of Posters
          • 464P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
          • 1290P - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program (EAP)
          • 509P - Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): a FIRE-3 analysis
          • 481P - Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial
          • 549P - Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: the plasma RAS wild type “window of opportunity”
          • 1068P - Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), a phase Ib – randomized phase II study versus single agent MTX
    • Archiv 2018
      • Cancer Academy - Blut- und Lymphdrüsenkrebs
      • Comprehensive Cancer Center Zürich: Third Zurich Immuno-Oncology Symposium
        • Keynote address
        • Clinical results, patient cases and future developments I
        • Clinical results, patient cases and future developments II
        • Clinical results, patient cases and future developments III
        • Developments in immunotherapy
      • 20th World Congress on Gastrointestinal Cancer (WCGIC 2018)
        • Session I: Welcome with Selected Abstracts
        • Session II: Cancer of the Pancreas and Biliary Tract - Selected Abstracts
        • Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
        • Pancreatic Cancer: Poster Session
        • Session VII: Gastric Cancer: Presentation of selected abstracts
        • Session VIII: Diseases and Cancers of the Liver: Presentation of a selected abstract
        • Session XI: Presentation of Selected Abstracts: Colorectal Cancer
        • Session XX: Colorectal Cancer: Presentation of selected abstracts
      • 23rd Congress of EHA
        • Presidential Symposium
        • Plenary Session Abstracts
        • Press Briefings
          • Press Briefing Day 1
          • Press Briefing Day 2
        • Important AML Presentations
          • IDHm and BCL2 inhibitors in AML
          • One AML Poster
        • Important CLL Presentations
        • Important Multiple Myeloma Presentations
          • Advances in front-line treatment of newly diagnosed multiple myeloma
          • New therapeutic strategies to improve the outcome of relapsed/refractory plasma cell disorders
          • Multiple Myeloma Poster Presentations
          • One Multiple Myeloma Late Breaking Abstract
        • Important Lymphoma Presentations
        • Thalassemia (2 Presentations) & MDS (1 Presentation)
      • Annual Meeting of the American Society of Clinical Oncology 2018
        • Highlights of the day
          • Sunday
          • Monday
          • Tuesday
        • Press Briefings
          • May 16 Presscast
          • Press Briefing 1 Friday June 1:
          • Press Briefing 2 Saturday June 2:
          • Press Briefing 3 Sunday June 3:
          • Press Briefing 4 Monday June 4:
        • Breast Cancer
          • Breast Cancer News from Oral Sessions
          • Breast Cancer News from Poster Sessions
          • Breast Cancer News Interviews
        • Colon Cancer
          • Colon Cancer News from Poster Sessions
        • Lung Cancer
          • Lung Cancer News from oral sessions
        • Lymphoma
          • Lymphoma News Oral Sessions
          • Lymphoma News Poster Sessions
        • Merkel-Cell Carcinoma
        • Myeloid Diseases
          • Myeloid Diseases News from Oral Sessions
          • Myeloid Diseases News from Poster Sessions
        • Other Hematologic Malignancies
        • Pancreatic Cancer
          • Pancreatic Cancer News from Oral Sessions
          • Pancreatic Cancer News from Poster Sessions
        • Urologic Cancers
          • Renal Cancer
      • ESMO Preceptorship on Colorectal Cancer 2018
      • SENOLOGIE update 2018
        • Prophylaktische Mastektomie - Moderation: M. Knauer, St. Gallen
        • Psychosoziale Konsequenzen des Mammakarzinoms - Moderation: E. Sarasin, Zürich
        • Update Systemtherapie - Moderation: U. Breitenstein, Zürich
        • Varia - Moderation: E. Saurenmann, Zürich
      • Cancer Academy - Darmkrebs
      • AACR Annual Meeting 2018, April 14-18,
        • Highlights presented at the Press Conference Sunday, April 15
        • Highlights presented at the Press Conference Monday, April 16
        • Highlights presented at the Press Conference Tuesday, April 17
      • ELCC 2018 (European Lung Cancer Congress)
        • Highlights - Press Releases
        • Interviews
          • Conference Highlights
          • Interviews in Cooperation with the Video Journal of Oncology - Part 1
        • SAKK 16/14 – Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
      • 11th European Breast Cancer Conference (EBCC-11)
        • Press conferences
        • Important News
        • Interviews
          • PD Dr. med. Christian Kolberg, Bottrop
          • Prof. Dr. med. Thorsten Kühn, Esslingen
          • Prof. Dr. med. Nadia Harbeck, München
      • St. Gallen International Gastrointestinal Cancer Conference Primary Therapy of Early GI Cancers -
        • Session 1: Oesophago-Gastric Cancer: One Disease or Separate Entities?
        • Session 2: Treatment of Oesophago-Gastric Cancer: Setting the Stage – Who Benefits from Multimodal Therapy
        • Session 3: Treatment Modalities for Oesophago-Gastric Cancer
        • Session 4: Special situation I: Signet Ring Cell Cancer
        • Keynote: Hereditary Gastric Cancer
        • New Therapy Options by metastatic Colorectal Cancer
        • Session 5: Special situation II: Limits of Curative Approaches to Metastatic Oesophago-Gastric Cancer
        • Session 6: Ready for Practice?
        • EORTC Gastrointestinal Tract Cancer Group:
      • Cancer Academy - Prostatakrebs
      • Promoting Self-efficacy with Digital Tools
        • Welcome (German)
        • Promoting patients’ self-efficacy: How can it be successful? (German)
        • United Kingdom’s perspective on the use of digital solutions to improve cancer patients’ self-efficacy
        • Presentation of selected digital and patient-oriented applications
          • Consilium: Patient-centered communication for improved self-efficacy and quality of life
          • STREAM – Ein online Programm zur Unterstützung bei Belastung während einer Krebserkrankung
          • Symptom Navi: Förderung des Selbstmanagements von Symptomen bei Krebs
          • Entspannung und Achtsamkeit für Krebspatienten mit Hilfe einer App (CanRelax)
          • FertiOnco – an online approach to facilitate decision making in young female cancer patients regarding fertility preservation
        • The use of patient-reported outcomes to improve outcomes and quality in cancer care
        • Digital solutions for cancer patients: reach, (cost-) effectiveness and implementation
        • Discussion and Closing remarks (German)
      • Gastrointestinal Cancers Symposium Jan 18-20, 2018 San Francisco, California
        • Cancers of the Esophagus and Stomach
        • Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
          • Videostatements
          • Studies presented in oral sessions
          • Posters
          • Posters
        • Cancers of the Colon, Rectum, and Anus
          • Videostatement
          • Studies presented in oral sessions
          • Choice of Posters
    • Archiv 2017
      • 59th ASH Annual Meeting and Exposition
        • Late-Breaking Abstracts Session
        • AML
          • Oral Sessions
        • Multiple Myeloma
          • Oral Sessions
          • Choice of Posters
        • Lymphoma
          • Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)
          • Hodgkin Lymphoma and T/NK Cell Lymphoma
          • CLL: Therapy, excluding Transplantation:
        • Press Conferences
          • Novel Approaches to Hemophilia and Venous Thromboembolism Care
          • Engineering Solutions to Treat Inherited Blood Disorders
          • Enhancing Care in Hematologic Malignancies through Targeted Therapies
          • Driving Outcomes in Lymphoma, Myeloma with CAR T-Cell Therapies
          • Late-Breaking Abstracts
        • Interviews
          • Statement Christian Taverna, Münsterlingen
          • Statement Thorsten Zenz, Zürich
      • 40th Annual San Antonio Breast Cancer Symposium (SABCS)
        • General Sessions
          • GENERAL SESSION 1:
          • GENERAL SESSION 2:
          • GENERAL SESSION 3:
          • GENERAL SESSION 4:
          • GENERAL SESSION 5:
          • GENERAL SESSION 6:
        • Press Conferences
          • Wednesday December 6 @ 7:15 a.m.
          • Wednesday December 6 @ 12:15 p.m
          • Thursday December 7 @ 7:30 am
          • Friday December 8 @ 7:30 am
        • Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable
          • Roundtable Brustkrebs Deutschland
          • Roundtable mit Experten aus der Schweiz
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Dr. med. Hans-Christian Kolberg, Bottrop
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Wolfgang Janni, Ulm
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Christoph Thomssen, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Peyman Hadji, Marburg
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Michael Patrick Lux, Erlangen
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Cornelia Liedtke, Berlin (Kopie)
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Stefan Buchholz, Regensburg
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Prof. Dr. med. Thorsten Kühn, Esslingen
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit  Dr. phil. Ute Berndt, Halle-Saale
          • Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr.med. Michael Untch, Berlin-Buch
      • Cancer Academy – Hirntumoren
      • 7. Interdisziplinäres Prostatakarzinomsymposium
        • Grundlagen
        • Lokalisiertes & oligometastatisches Prostatakarzinom
        • Systemtherapien Prostatakarzinom
      • Advanced Breast Cancer 4th ESO-ESMO International Consensus Conference
      • Cancer Academy – Brustkrebs
      • ESMO 2017 Congress
        • Breast Cancer Highlights
          • Neoadjuvante Therapie bei luminalem, triple negativem oder HER2 positivem Brustkrebs
          • Luminaler Brustkrebs - wer braucht Chemotherapie?
          • CDK4-6 Inhibitoren beim metastasierten Brustkrebs
          • Abstract LBA10_PR ‘Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)’
          • Abstract 1472P_PR ‘Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients’
        • Gastrointestinal Carcinoma Highlights
          • Colorectal Cancer
          • Gastric Cancer
        • Head & Neck Cancer Highlights
          • PD Dr. med. Sacha Rothschild comments Head&Neck Cancer Studies
          • Abstract LBA45_PR ‘Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial’
          • 1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
          • 1. First line Cetuximab and Cisplatin with or without Paclitaxel/2. The observational ENCORE study: Cetuximab + platinum-based therapy
        • Lung Cancer Highlights
          • Prof. Martin Reck
          • PD Dr. AlessandraCurioni-Fontecedro
          • PD Dr. AlessandraCurioni-Fontecedro
          • Prof. Dr. med.Solange Peters
          • Alectinib: ALEX and ALUR trials show CNS benefit in NSCLC
        • Melanoma & Merkel Cell Carcinoma Highlights
          • Prof. Dr. med. Reinhard Dummer, Zurich
          • Prof. Dr. med. Olivier Michielin, Lausanne
        • Ovarian Cancer Highlights
        • Urogenital Cancer Highlights
          • Richard Cathomas, Chur, comments on the urogenital Carcinoma Highlights
          • Abstract LBA37_PR – ‘Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial’
        • Late breaking news
          • Opening Press Conference
          • LBA Press Conference: Lung cancer
          • Press Conference: Facing the challenges of life after cancer
          • LBA Press Conference: Breast cancer, Gynaecological cancers, Genito-urinary cancers
          • LBA Press Conference: Melanoma cancer
          • Wrap-Up press conference/Best of ESMO2017
      • Cancer Center Zürich Second - Zurich Immuno-Oncology Symposium
        • Welcome
        • Essentials of tumour immunology and immunotherapies
        • Clinical results, patient cases and future developments I
        • Clinical results, patient cases and future developments II
        • Clinical results, patient cases and future developments III
        • Management of toxicities
      • ESMO 19th World Congress on Gastrointestinal Cancer
        • Cancer of the Pancreas
          • Session II: Cancer of the Pancreas & bile Ducts
          • Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology
          • Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
          • Interview mit Prof. Gerald Prager, Wien
        • Colon Cancer Highlights
          • Session XIX: Colorectal Cancer
          • Prof. Dr. med. Bernhard Pestalozzi, UniversitätsSpital Zürich:
      • Die besonderen Bedürfnisse von Kindern und Jugendlichen mit Krebs
      • 14 The International Conference on Malignant Lymphoma (ICML)
        • Interviews & Introductory Press Conference
          • Introductory Press Conference
          • Lymphoma Therapy
          • Oncoletter Interviews in cooperation with VJHEMONC
        • Satellite Symposia
          • THE FIRST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE
          • CHEMOTHERAPY IN INDOLENT LYMPHOMA - DYING OR WELL ALIVE?
      • ASCO Annual Meeting 2017
        • ASCO Press Conferences
          • ASCO Annual Meeting 2017 Presscast May 17
          • ASCO Annual Meeting 2017 Presscast June 2
          • ASCO Annual Meeting 2017 Presscast June 3 Part 1
          • ASCO Annual Meeting 2017 Presscast June 3 Part 2
          • ASCO Annual Meeting 2017 Presscast June 4
          • ASCO Annual Meeting 2017 Presscast June 5
        • Online-Programm verbessert die Lebensqualität von Krebspatienten
        • Highlights Mammakarzinom
          • Brustkrebs Deutschland: Experten-Roundtable vom ASCO Annual Meeting 2017
          • HER2-positiver, primär metastasierter Brustkrebs
          • HER2-positiver metastasierter Brustkrebs
          • PARP-Inhibitoren bei Brustkrebs
          • Abemaciclib bei Brustkrebs-Hirnmetastasen
          • HER2-positiver, primär metastasierter Brustkrebs
          • Scalp-Cooling - Chemo ohne Haarverlust?
          • CDK 4-6 Inhibitoren: Palbociclib, Ribociclib, Abemaciclib
          • Ergebnisse der Aphinity-Studie für HER 2 neu-positiven Brustkrebs adjuvant
          • Stellungnahme zur Relevanz von Studienendpunkten und deren Akzeptanz am runden Tisch: Wir alle müssen umdenken!
          • Finale Ergebnisse der PlanB-Studie für klinische Hochrisikopatientinnen bzw. mit mittlerem bis hohem Risiko nach Genexpressionstest
          • Short-HER-Studie:Sind 9 Wochen Trastuzumab nicht schlechter als 1 Jahr?
          • I-Spy 2-Studie: Immuntherapie mit Pembrolizumab plus Standard neoadjuvante Therapie für Hochrisikopatientinnen
        • Highlights Ovarialkarzinom
          • LION Studie: Rolle der Lymphknotenentfernung bei Erstoperation des Eierstockkrebs
          • DESKTOP 3 Studie: Erneute OP beim Eierstockkrebs Rezidiv
          • Immuntherapie bei Vulva-, Zervix- und Ovarialkarzinom: gibt es schon Einsatzmöglichkeit?
          • PARP-Inhibitoren beim Eierstockkrebs: welcher, wann und wie lange?
        • Head & Neck Cancer Highlights
          • Highlights Head&Neck
          • Statements Sacha Rothschild, Jean Bourhis & Marco Merlano
          • Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)
        • Highlights Gastrointestinaltumoren
          • Upper GIT
          • Colon Cancer
          • Pancreatic Cancer
        • Haematologic Malignancies
      • ELCC 2017 Genf
      • Cancer Academy – Lungenkrebs: Früherkennung, Diagnose und Behandlung
      • SENOLOGIE update 2017
        • Radiologie - Moderation: F. Dammann, Zürich
        • Genetik - Moderation: R. Morant, Rapperswil
        • Qualitätssicherung in der Senologie - Moderation: C. Rageth, Zürich
        • Operative Therapie - Moderation: C. Tausch, Zürich
        • Das metastasierte Mammakarzionom - Moderation: A. Müller, Winterthur
        • Varia - Moderation: D. Fink, Zürich
      • 15th St.Gallen International Breast Cancer Conference
      • Symposium Thoracic Oncology – Guidelines and Beyond
        • Screening
        • Inquiring the molecular tumor characteristics
        • Shanghai meets Zürich
        • Treatment options in localized NSCLC
        • Multimodality approaches in rare thoracic tumors
        • Metastatic disease
    • Archiv 2016
      • Das elektronische Patientendossier: das Genfer Beispiel der Integration eines Spitals in eine Referenzgemeinschaft
      • IASLC 17TH WORLD CONFERENCE ON LUNG CANCER
        • Fachpressemitteilungen
          • Lungenkrebs-Weltkongress in Wien: Aktive Prävention, akkurate Diagnostik, aktuelle Fortschritte in der Behandlung
          • Mutations-Diagnostik setzt sich bei Lungenkrebs durch
          • Mikro-RNA zur Prognosebestimmung bei Mesotheliom-Erkrankungen
          • Therapeutische Impfung gegen Lungenkrebs:
          • Zweite Therapiechance für Lungenkarzinompatienten
      • 58th Annual Meeting of the American Society of Hematology
        • PRESS CONFERENCES
          • Developing Novel Therapies and Unique Delivery Methods to Improve Treatment for Bleeding Crises, Leukemia
          • Revolutionizing Sickle Cell Disease Care in the United States and Abroad
          • Improved Outcomes in Leukemia, Trauma Settings with Personalized Medicine Approaches
        • Choice of ASH presentations
          • 616: Acute Myeloid Leukemia
          • Lymphoma
          • 642. CLL
          • 653. Myeloma
          • 637. Myelodysplastic Syndromes
          • 904. Outcomes Research
          • 112. Thalassemia and Globin Gene Regulation
        • Interviews Best of ASH (Multiples Myelom, Lymphome)
      • Zürich, 25. November 2016: 6. Treffen von Krebspatientinnen und -patienten
      • ESMO-Congress, Oct 07-11, 2016 - Copenhagen, Denmark
        • Press Conferences
          • Friday 7 October - Opening Press Conference
          • Saturday 8 October Press Conference 1: Late Breaking Trials
          • Sunday 9 October Press Conference 2: Late Breaking Trials
          • Monday 10 October Press Conference 3: Late Breaking Trials
        • More Highlights
          • Metastatic Colorectal Cancer
      • Cancer Center Zürich First Zurich Immuno-Oncology Symposium
        • Essentials of tumour immunology and immunotherapies
        • Clinical results, patient cases and future developments I
        • Clinical results, patient cases and future developments II
        • Clinical results, patient cases and future developments III
        • Management of toxicities
        • Radiotherapy
      • Das elektronische Patientendossier als zentrales Instrument der interprofessionellen Zusammenarbeit in integrierten Versorgungsorganisationen
      • WCGIC - 18th World Congress on Gastrointestinal Cancer
        • Metastatic & non-metastatic Colorectal Cancer
          • Statements Ulrich Güller, Andreas Wicki, Thomas Winder
        • ESMO PRESS RELEASES
          • Regorafenib shows significant survival gains in refractory liver cancer
          • Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo
          • Chemoradiotherapy after surgery for gastric cancer shows similar outcomes to post-operative chemotherapy.
          • Anti-PD-L1 immunotherapy shows response in microsatellite-stable metastatic colorectal cancer in combination with MEK inhibition
        • Satellite Symposia
          • Developing a continuum of care for patients with metastatic pancreatic cancer: A case study-based debate
          • mCRC Myth-Busters reloaded: More facts for optimal patient benefit!
      • Zürich, 1. Juli 2016: 5. Treffen von Krebspatientinnen und -patienten
      • Bern, Donnerstag 29. Juni 2016: Den Patienten integrieren - ein Symposium der Nationale Strategie gegen Krebs:
      • The 21st EHA Annual Congress
        • EHA Highlights presented at the press conference
          • Friday June 10
          • Saturday June 11
      • 36. Jahrestagung Deutsche Gesellschaft für Senologie 25.–28. Mai 2016, Dresden
        • Das Wichtigste vom Tage
        • Lunchsymposium: Genomic Health – Oncotype DX
        • Interviews
      • SENOLOGIE update 2016
        • Diagnostik - Moderation: M. Bürge, Zürich
        • Operative Therapie - Moderation: C. Tausch, Zürich
        • Über- oder Untertherapie? - Moderation: D. Fink, Zürich
        • Update Onkologie - Moderation: H-J. Senn, St. Gallen
        • Varia - Moderation: E. Saurenmann, Zürich
      • ELCC 2016 | European Lung Cancer Conference - ESMO
        • News
          • Osimertinib given as first-line treatment may alter biology of EGFR mutated non-small-cell lung cancer
          • Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma
          • Patients with EGFR expressing non-small-cell lung cancer benefit most from necitumumab added to chemotherapy
          • Studies confirm benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer
        • Interviews
      • 3rd Gastrointestinal Cancer Conference
        • Thursday March 10
          • Session 1: Cystic Neoplasms of the Pancreas
          • Session 2: Biliary Tract - Extrahepatic Cholangiocarcinoma I
          • Keynote I: Molecular biology of pancreatic cancer
          • Session 3: Biliary Tract - Extrahepatic Cholangiocarcinoma II
          • Session 4: Cancer of the Ampulla of Vater
        • Friday March 11
          • Session 5: Understanding Pancreatic Cancer
          • Session 6: Resectable Pancreatic Cancer
          • Satellite symposium organized by Celgene
          • Session 7: Borderline Resectable Pancreatic Cancer
          • Session 8: Improving Outcome in Pancreatic Cancer
      • Symposium Nationale Strategie gegen Krebs:
      • WEF DAVOS: Cancer Moonshot: A Call to Action
  • Livecasts & Kongresskalender
    • Livecast
    • Kongresskalender 2019
    • Kongresskalender 2020
  • Drugs oral & i.v., Guidelines, Interaktionen
    • Orale Krebstherapeutika
      • orale Wirkstoffe A
      • orale Wirkstoffe B
      • Orale Wirkstoffe C
      • Orale Wirkstoffe D
      • Orale Wirkstoffe E
      • Orale Wirkstoffe G
      • Orale Wirkstoffe H
      • Orale Wirkstoffe I
      • Orale Wirkstoffe L
      • Orale Wirkstoffe Ν
      • Orale Wirkstoffe O
      • Orale Wirkstoffe P
      • Orale Wirkstoffe R
      • Orale Wirkstoffe S
      • Orale Wirkstoffe T
      • Orale Wirkstoffe V
    • Wirkstoffe
      • Melden Sie fehlende Wirkstoffe
      • Acronyme
      • ALK-Inhibitors
      • Wirkstoffe A
      • Wirkstoffe B
      • Wirkstoffe C
      • Wirkstoffe D
      • Wirkstoffe E
      • Wirkstoffe F
      • Wirkstoffe G
      • Wirkstoffe H
      • Wirkstoffe I
      • Wirkstoffe L
      • Wirkstoffe M
      • Wirkstoffe N
      • Wirkstoffe O
      • Wirkstoffe P
      • Wirkstoffe Q
      • Wirkstoffe R
      • Wirkstoffe S
      • Wirkstoffe T
      • Wirkstoffe V
      • Wirkstoffe Z
    • Behandlungsguidelines
    • Journal of Oncoletter
    • The Cancer Cell Line Encyclopedia
    • Texte zur Medizinischen Onkologie aus dem Swiss Medical Forum
    • Oncologic emergencies
    • Interaktionsprüfungen
    • Krebserkrankungen (Entstehung & Verlauf)
      • Krebserkrankungen B
      • Krebserkrankungen D
      • Krebserkrankungen E
      • Krebserkrankungen G
      • Krebserkrankungen H
      • Krebserkrankungen L
      • Krebserkrankungen M
      • Krebserkrankungen N
      • Krebserkrankungen P
      • Krebserkrankungen S
    • Wissenschaftlicher Beirat Oncoletter
  • Nebenwirkungen & Behandlungs- vorschläge
    • Symptome
      • Allgemeine Störungen
        • Fatigue
        • Fieber/Infektion
        • Ödeme
        • Schmerzen
        • Stimmungsschwankungen
      • Atmungsorgane
        • Dyspnoe
        • Epistaxis/Nasenbluten
        • Pleuraerguss
      • Augen
        • Konjunktivitis
        • Periorbitale Oedeme
        • Sehstoerungen
      • Blut- und Lymphsystem
        • Anaemie
        • Lymphopenie
        • Neutropenie
        • Thrombozytopenie
      • Gastrointestinale Störungen
        • Abdominalschmerz
        • Diarrhoe
        • Dyspepsie
        • Mukositis/Stomatitis
        • Nausea und Erbrechen
        • Obstipation
      • Haut
        • Aktinische Keratose
        • Alopezie
        • Hand-Fuss-Syndrom
        • Hyperkeratose
        • Photosensivitätsreaktion
        • Plattenepithelkarzinom der Haut
        • Praevention von Pruritus, Rash, Desquamation
        • Pruritus
        • Rash, papulopustulöse, follikuläre Exantheme
        • Seborrhoische Keratose
        • Sonnenbrand
        • Trockene Haut
      • Herz, Gefässe
        • Arterielle Hypertonie
        • Blutungen
        • Herzinsuffizienz
        • Hitzewallungen
        • Verminderung der linksventrikulären Auswurfsfraktion (LVEF)
      • Leber und Galle
        • Dosierungsempfehlungen oraler TKI/mTor-Inhibitoren bei Leberdysfunktion
        • Gamma-Glutamyl-Transferase
      • Muskelskelettsystem
        • Arthralgien
        • Knochenschmerzen
        • Muskelschwaeche
        • Muskelverhaertungen und Muskelkraempfe
        • Muskuloskelettale Beschwerden/Schmerzen in den Extremitaeten/Gliederschmerzen
        • Myalgie/Muskelschmerzen
        • Rueckenschmerzen
      • Nervensystem
        • Dysgeusie
        • Insomnie
        • Kopfschmerzen
        • Neuropathie/Polyneuropathie
        • Reversible posteriore Leukenzephalopathie
      • Niere und ableitende Harnwege
        • Harnwegsinfekt
      • Stoffwechsel- und Ernährungsstörungen
        • Amylase-/Lipasewerte
        • Anorexie
        • Cholesterol- oder Triglyzeridwerte
        • Gewichtszunahme
        • Glucosewerte
        • Hypokaliämie
        • Hypokalzämie
        • Hypophosphatämie
        • Hypothyreose
    • Referenzen
    • Nutzungsbestimmungen
  • Organisationen
    • Fachgesellschaften
    • Info für PatientINNen
    • Netzwerke
 
Startseite Kongressberichte & Archiv SABCS - 41st Annual San Antonio Breast Cancer Symposium Press Conferences Thursday, Dec. 6 Press Conference

Program & Webcasts

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Slides

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Slides

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Slides

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Slides

 
Navigation überspringen
  • SABCS - 42nd Annual San Antonio Breast Cancer Symposium
  • 61st ASH Annual Meeting and Exposition
  • 8. Interdisziplinäres Prostatakarzinom-Symposium 2019
  • Cancer Academy – Immuntherapie
  • Jahrestagung 2019 von DGHO, OeGHO, SGMO und SGH+SSH
  • OnkoZentrum Zürich - Patientenforum 2019
  • ESMO 2019
  • Cancer Academy - Kopf-Hals-Tumore
  • CAR-T-Zell Therapie in der Schweiz
  • IASLC 2019 World Conference on Lung Cancer (#WCLC19)
  • 4th Zurich Immuno-Oncology Symposium
  • ESMO World Congress on Gastrointestinal Cancer
  • Second Zurich Lung Cancer Symposium
  • 15th International Conference on Malignant Lymphoma (ICML)
  • 24th Congress of EHA
  • Annual Meeting of the American Society of Clinical Oncology 2019
  • Senologie Update 2019
  • ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland
  • 45th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
  • BCC2019
  • AGO MAMMAKARZINOM - State of the Art Meeting 2019
  • First Zürich Precision Oncology Symposium
  • The Gastrointestinal Cancers Symposium 2019
  • SABCS - 41st Annual San Antonio Breast Cancer Symposium
    • Press Conferences
      • Wednesday, Dec. 5, Press Conference 1
      • Wednesday, Dec. 5, Press Conference 2
      • Thursday, Dec. 6 Press Conference
      • Friday, Dec. 7 Press Conference
    • Schweizer Poster am SABCS
    • Interviews - Breast Cancer
    • Schweizer Expertenrunde mit einigen Highlights vom SABCS:
    • Round Table mit Brustkrebs Deutschland e.V.
    • General Sessions
  • American Society of Hematology (ASH) 60th Annual Meeting and Exposition
  • Cancer Academy: Sarkome, Früherkennung, Diagnose und Behandlung
  • ESMO 2018 Congress
  • Archiv 2018
  • Archiv 2017
  • Archiv 2016
 

    News

  • Den diesjährigen Robert Wenner-Preis für junge Krebsforschende verleiht die Krebsliga Schweiz an Andrea Alimonti.

    21-11-2019 19:19
    Weiterlesen ...

  • BAG bestätigt Ausdehnung der Erstattung von Kisqali® durch die obligatorische Krankenversicherung ab 1. 11.19 auf folgende Indikationen:

    07-11-2019 20:18
     
     
     
    Weiterlesen ...

  • NEU: CYRAMZA® (Ramucirumab) seit Okt. 2019 – erstattet auch für mCRC

    16-10-2019 16:43

    (www.swissmedicinfo.ch; www.spezialitätenliste.ch)

    Weiterlesen ...

Newsletter

Ja  Nein 
Neu laden
Bitte geben Sie den Schriftzug ein!

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Kongressorganisatoren beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weitere Finanzierungsquellen werden bei den jeweiligen Berichten aufgeführt. Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren.

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
POSTFACH 412
CH-8201 SCHAFFHAUSEN

Mail: info[@]oncoletter.ch